---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-114304"
form_type: "8-K"
ticker: "RYTM"
cik: "0001649904"
company_name: "RHYTHM PHARMACEUTICALS, INC."
filed_at: "2024-11-05T23:59:59+00:00"
generated_at: "2026-05-30T05:23:13.842710+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Rhythm Pharma Q3 revenue $33.3M (+14% seq); FDA Priority Review for label expansion to age 2

## Summary
- IMCIVREE net revenue $33.3M (Q3 2024), up 48% YoY from $22.5M; US sales $23.3M (+8% seq), ex-US $10.0M (+35% seq).
- Net loss $(45.0)M ($(0.73)/share) vs $(44.2)M ($(0.76)/share) in Q3 2023; cash $298.4M at Sep 30, 2024.
- FDA accepted sNDA for Priority Review to treat children as young as 2 years; PDUFA date Dec 26, 2024.
- Phase 3 hypothalamic obesity trial top-line data on track for 1H 2025; early-access French data showed 12.8% BMI reduction at 3 months.
- FY 2024 non-GAAP operating expense guidance narrowed to $245-255M from $250-270M.

## SEC filing metadata
- accession: 0001104659-24-114304
- form_type: 8-K
- ticker: RYTM
- cik: 0001649904
- company_name: RHYTHM PHARMACEUTICALS, INC.
- filed_at: 2024-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/0001104659-24-114304-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649904/000110465924114304/tm2427018d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-114304
- JSON: https://secwatch.observer/filing/0001104659-24-114304.json
- Plain text: https://secwatch.observer/filing/0001104659-24-114304.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.